Prevalence of Hepatitis B in Vallés Occidental. Observational Multicentric Study
NCT ID: NCT02548325
Last Updated: 2019-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1001 participants
OBSERVATIONAL
2014-06-01
2017-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hepatitis B Virus Prevalence and Risk Factors in Belgium
NCT03425513
Coexistence HBsAg/HBcAC, Clinical Characterístics & Outcomes
NCT05446532
Molecular Epidemiology of Hepatitis B in Cayenne General Hospital, French Guiana
NCT04886102
Hepatitis B Prevalence in the Turkish Population Living in Middle Limburg
NCT03396458
"Real-life" Cohort of Patients With Chronic Hepatitis B Virus Infection
NCT01732081
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The prevalence in Spain is estimated at a 2-7 % and is considered a second intermediate prevalence.
For over 20 years, has carried out a program of primary prevention through universal vaccination against hepatitis B including it in the childhood vaccination schedule and has already been observed that in some estudi3 the prevalence has declined . For this reason , we want to evaluate what is the currently prevalence in our area of influence. There aren't recent studies to assess what is the current status of these patients ( how many , what risk factors which needs of treatment and with answer ...)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Not apply
None. Just registration epidemiology dates
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Duplicity on record
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Mutua de Terrassa
OTHER
Consorci Sanitari de Terrassa
OTHER
Corporacion Parc Tauli
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mireia Miquel-Planas
phD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mútua de Terrassa
Terrassa, Barcelona, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CorporacionPT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.